Cancer Stem Cells and Targeting Strategies
Open Access
- 18 August 2019
- Vol. 8 (8), 926
- https://doi.org/10.3390/cells8080926
Abstract
Chemoresistance is a major problem in cancer therapy as cancer cells develop mechanisms that counteract the effect of chemotherapeutic compounds, leading to relapse and the development of more aggressive cancers that contribute to poor prognosis and survival rates of treated patients. Cancer stem cells (CSCs) play a key role in this event. Apart from their slow proliferative property, CSCs have developed a range of cellular processes that involve drug efflux, drug enzymatic inactivation and other mechanisms. In addition, the microenvironment where CSCs evolve (CSC niche), effectively contributes to their role in cancer initiation, progression and chemoresistance. In the CSC niche, immune cells, mesenchymal stem cells (MSCs), endothelial cells and cancer associated fibroblasts (CAFs) contribute to the maintenance of CSC malignancy via the secretion of factors that promote cancer progression and resistance to chemotherapy. Due to these factors that hinder successful cancer therapies, CSCs are a subject of intense research that aims at better understanding of CSC behaviour and at developing efficient targeting therapies. In this review, we provide an overview of cancer stem cells, their role in cancer initiation, progression and chemoresistance, and discuss the progress that has been made in the development of CSC targeted therapies.Keywords
This publication has 175 references indexed in Scilit:
- Drug resistance: Still a daunting challenge to the successful treatment of AMLDrug Resistance Updates, 2012
- Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapyCell Death & Differentiation, 2011
- The critical role of CD133+CD44+/high tumor cells in hematogenous metastasis of liver cancersCell Research, 2011
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- Primary Tumor Genotype Is an Important Determinant in Identification of Lung Cancer Propagating CellsCell Stem Cell, 2010
- Stem Cells and the Niche: A Dynamic DuoCell Stem Cell, 2010
- Heterogeneity in Cancer: Cancer Stem Cells versus Clonal EvolutionCell, 2009
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical OutcomeCell Stem Cell, 2007
- Molecular mechanisms of drug resistanceThe Journal of Pathology, 2005